دورية أكاديمية
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.
العنوان: | Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. |
---|---|
المؤلفون: | Evans JP; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Winiarski BK; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Sutton PA; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Jones RP; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Ressel L; Department of Veterinary Pathology, Institute of Veterinary Science, University of Liverpool, Liverpool, United Kingdom., Duckworth CA; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Pritchard DM; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Lin ZX; School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, People's Republic of China., Fretwell VL; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Tweedle EM; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Costello E; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Goldring CE; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Copple IM; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Park BK; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Palmer DH; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.; Clatterbridge Cancer Centre, Liverpool, United Kingdom., Kitteringham NR; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. |
المصدر: | Oncotarget [Oncotarget] 2019 Jan 18; Vol. 10 (6), pp. 685. Date of Electronic Publication: 2019 Jan 18 (Print Publication: 2019). |
نوع المنشور: | Journal Article; Published Erratum |
اللغة: | English |
بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
مستخلص: | [This corrects the article DOI: 10.18632/oncotarget.25497.]. |
التعليقات: | Erratum for: Oncotarget. 2018 Jun 5;9(43):27104-27116. (PMID: 29930754) |
معلومات مُعتمدة: | 15957 United Kingdom CRUK_ Cancer Research UK |
تواريخ الأحداث: | Date Created: 20190219 Latest Revision: 20240210 |
رمز التحديث: | 20240210 |
مُعرف محوري في PubMed: | PMC6363008 |
DOI: | 10.18632/oncotarget.26625 |
PMID: | 30774766 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!